Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Das, Tamal Kusum
- Design and Development of Valsartan Loaded Nanostructured Lipid Carrier for the Treatment of Diabetic wound Healing
Abstract Views :156 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutics, JSS College of Pharmacy, Ooty, IN
2 JSS Academy of Higher Education and Research, Mysuru, IN
1 Department of Pharmaceutics, JSS College of Pharmacy, Ooty, IN
2 JSS Academy of Higher Education and Research, Mysuru, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 6 (2019), Pagination: 2922-2928Abstract
Diabetes mellitus is a group of metabolic diseases identified by hyper glycaemia that results from defects in insulin secretion, insulin action or both. It can also be referred as metabolic disorder. The main objective of this research is to enhance the protection of wound healing from the valsartan loaded Nanostructure Lipid carrier. Valsartan is the angiotensin II antagonist drug, which is of BCS class II category. Nanostructure lipid carrier is a colloidal carrier system which is having many advantages such as improvement in Bioavailability, Increase in the solubility and therapeutic efficacy. The prepared Nanostructure lipid carrier was consisting of palmitic acid as solid lipid and soya oil as liquid lipid were prepared by melt emulsification method. Optimization and Characterization of Valsartan loaded NLCs have been done by DSC, FT-IR, Particle size, Zeta potential, Scanning Electron microscopy, Stability study, Entrapment efficiency, Release kinetics and In-vitro drug release studies. The In-vivo have also been done for the treatment of Diabetic wound healing. In Conclusion, it is shown that the valsartan loaded Nanostructure lipid carrier formulation was very effectively for the treatment of Diabetic wound Healing.Keywords
Diabetic Wound Healing, Nanostructured Lipid Carrier, Valsartan, Drug Release, In-vivo Studies.References
- Guo, S. and Di Pietro, L. A. Critical review in oral biology and medicine: Factors affecting wound healing. Journal of Dental Research, 2010; 89: 219–229.
- Chan, M. Global report on diabetes. World Health Organization, 2014; 58: 1–88.
- Ekambaram, P., Sathali, a A. H. and Priyanka, K. Solid Lipid Nanoparticles : Scientific Reviews and Chemical Communications, 2012; 2: 80–102.
- Fu-Qiang Hu, Sai-Ping Jiang, Yong-Zhong Du, Hong Yuan, Yi-Qing Ye, S. Z. Preparation and characterization of monostear in nanostructured lipid carriers. International Journal of Pharmaceutics, 2006;314: 83–89.
- Perkins, F.M., Kehlet, H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology,2000; 93: 1123–1133.
- Olbrich C, Gebner A, Kayser O, M. R. Lipid–drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. Journal of Drug Targeting, 2002, 10:387–96.
- Müller, R. H., Petersen, R. D., Hommoss, A. and Pardeike, J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Advanced Drug Delivery Reviews, 2007, 59: 522–530.
- Radtke M, Souto EB, M. R. Nanostructured lipid carriers: a novel generation of solid lipid drug carriers. Pharmaceutical technology Europe, 2005; 17: 45–50.
- Al., R. J. P. and Z. P. P. et. Formulation optimization and Evaluation of Nano structured Lipid Carrier Containing Valsartan. International Journal of Pharmaceutical Sciences and Nanotechnology
- Albekery, M. A. et al. Optimization of a nanostructured lipid carriers system for enhancing the biopharmaceutical properties of valsartan. Digest Journal of Nanomaterials and Biostructures, 2017, 12: 381–389.
- KB CS, R. B. Formulation, optimization and in vitro evaluation of lipid nanoparticles Containing anti-hypertensive drug. International Journal of Research in Pharmaceutical Sciences, 127–30.
- Kaur, K., Nautiyal, U. and Singh, D. Nanostructured lipid carrier for bioavailability enhancement, 2015, 2: 1–9.
- Yang, C.-R. et al. Preparation, optimization and characteristic of huperzine a loaded nanostructured lipid carriers. Chemical and Pharmaceutical Bulletin,2010, 58: 656–661.
- Thanki, K., Kulthe, S., Mandge, Y. and Rao, M. R. P. Formulation development and IVIVC of controlled porosity osmotic pump tablets of carvedilol phosphate. Journal of Pharmacy Research, 2011; 4: 4736–4740.
- Abousamra, M. M. and Mohsen, A. M. Solid lipid nanoparticles and nanostructured lipid carriers of tolnaftate: Design, optimization and in-vitro evaluation. International Journal of Pharmacy and Pharmaceutical Sciences, 2016; 8: 380–385.
- Sharma, R., Yasir, M., Bhaskar, S. and Asif, M. Formulation and evaluation of paclitaxel loaded psa-peg nanoparticles. Journal of Applied Pharmaceutical Science, 2011; 1: 96–98.
- Kumar, B. P., Chandiran, I. S. and Jayaveera, K. N. Formulation and evaluation of glimepiride loaded cellulose acetate microparticles. International Journal of Pharmacy and Pharmaceutical Sciences,2014; 6: 511–515.
- Harmonized Tripartite guideline for stability testing of new drugs substances and products Q1A (R2) International Conference on Harmonization (ICH)2003.